A. Nattermann & Cie Gmbh

Rhone Poulenc Rorer

Rhone-Poulenc Rorer S.a.

Manfred Durr

Jorg Hager

Armin Wendel

Benedikt Gajdos

Jorg-Christian Hager

Miklos Ghyczy

Sigurd Leyck

Jurgen Seidel

Winfred Jettka

Hans-Ulrich Fribolin

Helmut Wetzig

Ekkerhard Harhausen

Hans U Fribolin

Ernst Lunebach

Winfried Jettka

Klaus-Dieter Gneuss

Ekkehard Harhausen

Volker Schulz

A pharmaceutical, orally applicable composition is disclosed, whereby the composition contains at least one antacid active substance as well as more than 45% by weight of a sugar and/or sugar alcohol and between 12% and 35% by weight of water. The composition has a liquid or a semisolid consistency and is substantially free of preservatives.

Pharmaceutical, orally applicable composition

A pharmaceutical, orally applicable composition is described, whereby the solid composition contains at least one antacid active ingredient and/or at least one H.sub.2 -antagonist, at least one disintegrant, as well as at least one usual pharmaceutical additional ingredient. Furthermore said composition contains at least one ingredient that accelerates the decomposition of said composition in the mouth or in a liquid, whereby said ingredient is a water-soluble amino acid, a water-soluble amino acid derivative and/or a water-soluble amino acid salt.

A pharmaceutical, orally applicable composition is described, whereby the solid composition contains at least one active ingredient, at least one disintegrant, as well as at least one usual pharmaceutical additional ingredient. Furthermore said composition contains at least one ingredient that accelerates the decomposition of said composition in the mouth or in a liquid, whereby said ingredient is a water-soluble amino acid, a water-soluble amino acid derivative and/or a water-soluble amino acid salt.

A pharmaceutical, oral composition of a liquid to semisolid consistency is disclosed, wherein the composition, substantially free of preservatives, contains at least one antacid active substance as well as more than 45% by weight, a sugar and/or sugar alcohol, relative to the ready-to-use composition, and up to 40% by weight, a pharmaceutically harmless solvent, relative to the ready-to-use composition.

Antacid composition, substantially free of preservatives

An aqueous liposome system which contains at least one phospholipid and selectively a non-toxic organic solvent. In addition to the at least one phospholipid the liposome system contains at least one phospholipidic charge carrier.

Water-containing liposome system

This invention relates to a pharmaceutical composition comprising as active principle, docetaxel or a taxoid derived from docetaxel, one or more unsaturated phospholipids and a small amount of one or more negative phospholipids, allow the active principle to be formulated in high concentration and are suitable for administration by injection.

Pharmaceutical composition based on taxoids

Use of glycofurol for the liquidization of pharmaceutical preparations containing more than 50% phosphatidyl choline with a high content of unsaturated fatty acids, which preparations can contain another active ingredient as well as phosphatidyl choline, and in which the viscosity so obtained permits filling into soft gelatine capsules.

Use of glycofurol for the liquidization of pharmaceutical preparations

Pharmaceutical preparation containing phospholipids for the therapeutic treatment of rheumatic diseases which contain in addition to the antiphlogistically acting oxicam derivatives of the general formula ##STR1## special 1,2-diacyl-glycero-3-phosphocholines wherein 75-86% by weight of the acyl radicals are unsaturated fatty acid radicals, and the preparation thereof.

Pharmaceutical preparation for the therapeutic treatment of rheumatic

Pharmaceutical formulations for the treatment of gastrointestinal disorders, which contain as the active component an effective gastrointestinal disorder alleviating amount of a 1,2-diacylglycero-3-phosphocholine in which 75-86% by weight of the acyl radicals are unsaturated fatty acid radicals having a chain length of 16, 18 or 20 carbon atoms. The mixtures of fatty acid radicals in the acyl groups in the 1- and 2-positions preferably have different compositions. The formulations can also contain other active compounds, in particular those which display injurious gastrointestinal side effects.

Formulation with special 1,2-diacylglycero-3-phosphocholines for the

Stable pharmaceutical preparations comprising amitriptylin oxide dihydrate as an active substance and an organic acid from the group of hydroxy carboxylic acids, ketocarboxylic acids or amino acids as a stabilizer besides conventional pharmaceutical auxiliaries and carrier substances.

Pharmaceutical amitriptylin oxide preparation and process for its

The present invention is related to a process for filling pharmaceutical products which contain 10 to 98% by weight of a phospholipide and which are highly viscous at room temperature, into hard capsules by admixing to such products a solvent or mixture of solvents in particular amounts, said solvent or solvent mixture having particular evaporation properties, and ejecting the resulting product from a usual filler nozzle under particular conditions, and closing the filled capsule with its cap.

Process for filling pharmaceutical products containing phospholipides

The present invention is related to a process for filling pharmaceutical products which are highly viscous at room temperature, into hard capsules by admixing to such products a solvent or mixture of solvents in particular amounts, said solvent or solvent mixture having particular evaporation properties, and ejecting the resulting product from a usual filler nozzle under particular conditions, and closing the filled capsule with its cap.

Growing community of inventors

Bergheim-Glessen, Germany

Manfred Durr